



THE UNITED STATES PATENT AND TRADEMARK OFFICE

#2411
RECEIVED
SEP 27 2001

SEP 27 2001

TECH CENTER 1600/2900

In re the application of:

DE FLORA et al.

Group Art Unit: 1623

Serial Number: 09/125,022

Examiner: H. Owens, Jr.

Filed: November 24, 1998

Atty. Docket No. 108903-08035

For: PHARMACEUTICAL COMPOSITION ENABLING TO INHIBIT CANCER
METASTASIS FORMATION CONTAINING N-ACETYL-CYSTEINE AND
DOXORUBICIN

AMENDMENT UNDER 37 C.F.R. 1.116

Commissioner for Patents
Washington, D.C. 20231

September 23, 2001

Dear Sir:

In response to the Office Action mailed May 23, 2001, the period for response being extended one month from August 23, 2001 until September 24, 2001 by the attached Petition for Extension of Time, please make the following changes in the application as follows:

IN THE CLAIMS:

Please amend claim 15 as follows:

--15. (Amended) The method according to claim 13, wherein the doxorubicin is administered in an amount between 2 and 10 mg per dose.--

REMARKS

Claims 13-15 remain pending herein.

Claims 13-15 were rejected under § 103 as being unpatentable over Freeman et al